Presentation is loading. Please wait.

Presentation is loading. Please wait.

Cytokeratin 19 Fragment Predicts the Efficacy of Epidermal Growth Factor Receptor– Tyrosine Kinase Inhibitor in Non–Small-Cell Lung Cancer Harboring EGFR.

Published byAgata Kozłowska Modified over 5 years ago

Similar presentations

Presentation on theme: "Cytokeratin 19 Fragment Predicts the Efficacy of Epidermal Growth Factor Receptor– Tyrosine Kinase Inhibitor in Non–Small-Cell Lung Cancer Harboring EGFR."— Presentation transcript:

1 Cytokeratin 19 Fragment Predicts the Efficacy of Epidermal Growth Factor Receptor– Tyrosine Kinase Inhibitor in Non–Small-Cell Lung Cancer Harboring EGFR Mutation  Kosuke Tanaka, MD, Akito Hata, MD, Reiko Kaji, MD, Shiro Fujita, MD, PhD, Takehiro Otoshi, MD, Daichi Fujimoto, MD, Takahisa Kawamura, MD, Koji Tamai, MD, Jumpei Takeshita, MD, Takeshi Matsumoto, MD, Kazuya Monden, MD, Kazuma Nagata, MD, Kyoko Otsuka, MD, Atsushi Nakagawa, MD, Ryo Tachikawa, MD, Kojiro Otsuka, MD, PhD, Keisuke Tomii, MD, PhD, Nobuyuki Katakami, MD, PhD  Journal of Thoracic Oncology  Volume 8, Issue 7, Pages (July 2013) DOI: /JTO.0b013e31828c3929 Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Kaplan–Meier survival curves of progression-free survival (PFS) according to (A) serum cytokeratin 19 fragment (CYFRA) and (B) carcinoembryonic antigen (CEA) level. The median duration of PFS in patients with high- and normal serum CYFRA 21-1 level was 7.5 months (95% confidence interval [CI], 6.2–9.1 months) and 13.3 months (95% CI, 10.6–18.2 months), respectively (p < 0.001). The median durations of PFS in the two groups of patients with high- and normal-serum CEA levels were 8.6 months (95% CI, 7.6–11.9 months) and 11.2 months (95% CI, 7.1–16.6 onths), respectively (p = 0.242). Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31828c3929) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Kaplan–Meier survival curves of overall survival according to (A) serum cytokeratin 19 fragment and (B) carcinoembryonic antigen level. Kaplan–Meier survival curves of postprogression survival according to (C) serum cytokeratin 19 fragment and (D) carcinoembryonic antigen level. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31828c3929) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Cytokeratin 19 Fragment Predicts the Efficacy of Epidermal Growth Factor Receptor– Tyrosine Kinase Inhibitor in Non–Small-Cell Lung Cancer Harboring EGFR."

Similar presentations

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304  Martin J. Edelman, MD, Lydia.

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB   Martin J. Edelman, MD, Lydia.
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 
Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations:

Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations:
Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Crizotinib administered via nasogastric and percutaneous endoscopic gastrostomy tubes for the successful treatment of ALK-rearranged lung cancer in a.

Crizotinib administered via nasogastric and percutaneous endoscopic gastrostomy tubes for the successful treatment of ALK-rearranged lung cancer in a.
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection  Morihito Okada,

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection  Morihito Okada,
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 
Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer 

Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer 
Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C
The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,
Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.
Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.
The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

Similar presentations

Ads by Google